Status:
UNKNOWN
"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.
Lead Sponsor:
Sohag University
Conditions:
Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Eligibility:
All Genders
18+ years
Brief Summary
Atrial fibrillation (AF) is type of arrhythmia characterized by an irregular and often rapid heartbeats, it has strong associations with other cardiovascular diseases, such as heart failure, coronary ...
Eligibility Criteria
Inclusion
- All patients with atrial fibrillation :
- Aged 18 years old or older .
- Underwent cardiac valve replacement
- Who have valvular heart disease receiving anticoagulants .
- Who have non valvular AF in whom CHA2DS 2VASc score 2 or more.
- Receiving either vitamin K antagonist e.g warfarin or NOAC .
Exclusion
- Patients age less than 18 years old
- Patients receiving anticoagulants without atrial fibrillations
- Pregnant patients with AF
- Patients with AF on Non oral anticoagulants
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05975320
Start Date
August 1 2023
End Date
February 1 2024
Last Update
August 3 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.